Gilead Sciences (GILD) stock
Health Care · Biotechnology
Gilead Sciences (GILD) is a Biotechnology company in the Health Care sector, headquartered in Foster City, California. As of October 23, 2026, GILD closed at $156.04, a market capitalization of $193.48 billion, the 58th largest company in the S&P 500. Over the last twelve months it generated $30.46 billion in revenue (+10% year over year) and $12.94 billion in free cash flow.
- 1-year total return: +32.4% (dividends reinvested)
- 5-year return: +22.6% a year
- 52-week range: $114.02 – $160.51
- Gross margin 79.6%, operating margin 33.7%
- Dividend yield: 2.10%, 10 straight years of increases
- FI Handbook report card: B- across 10 metrics
- 8th largest of 60 Health Care stocks in the S&P 500
GILD price chart
1Y price change: +29.2% (price only; total returns below include dividends)
| Total return | 1M | YTD | 1Y | 3Y | 5Y | 10Y | MAX |
|---|---|---|---|---|---|---|---|
| GILD | +3.1% | +29.4% | +32.4% | +30.3% | +22.6% | +11.6% | +18.5% |
Dividends reinvested. 3Y and longer are annualized; MAX is annualized since 1992.
GILD key statistics
- Market cap
- $193.5B
- #58 in S&P 500
- P/E (TTM)
- —
- Forward P/E
- 15.6x
- EPS (TTM)
- $-2.65
- Revenue (TTM)
- $30.5B
- +10%
- Free cash flow
- $12.9B
- Gross margin
- 79.6%
- Operating margin
- 33.7%
- Return on equity
- -20.7%
- Dividend yield
- 2.10%
- 52-week range
- $114.02 – $160.51
- Beta
- 0.33
- Price / sales
- 6.4x
- EV / EBITDA
- 14.7x
- Debt / equity
- 2.23x
- Employees
- 17,000
GILD report card
B-Ten fundamentals graded A to F against fixed thresholds. Not a buy or sell rating.
- Revenue growth10.2%B
- Gross margin79.6%A
- Operating margin33.7%A
- FCF margin42.5%A
- Return on equity-20.7%F
- Net debt / EBITDA1.5xC
- Forward P/E15.6xB
- PEG ratio2.3xD
- Shareholder yield3.1%B
- Share count change / yr-0.1%C
Gilead Sciences financials
Revenue went from $30.4B in fiscal 2016 to $29.4B in fiscal 2025, shrinking 0.4% a year.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $30.4B | $26.1B | $22.1B | $22.4B | $24.7B | $27.3B | $27.3B | $27.1B | $28.8B | $29.4B |
| Gross profit | $26.1B | $21.7B | $17.3B | $17.8B | $20.1B | $20.7B | $21.6B | $20.6B | $22.5B | $23.2B |
| Operating income | $17.6B | $14.1B | $8.2B | $4.3B | $4.1B | $9.9B | $7.3B | $7.6B | $1.7B | $10.0B |
| Net income | $13.5B | $4.6B | $5.5B | $5.4B | $123.0M | $6.2B | $4.6B | $5.7B | $480.0M | $8.5B |
| EPS (diluted) | $9.94 | $3.51 | $4.17 | $4.22 | $0.10 | $4.93 | $3.64 | $4.50 | $0.38 | $6.78 |
| Free cash flow | $16.3B | $11.3B | $7.5B | $8.3B | $7.5B | $10.8B | $8.3B | $7.4B | $10.3B | $9.5B |
| Buybacks | $11.0B | $954.0M | $2.9B | $1.7B | $1.6B | $546.0M | $1.4B | $1.0B | $1.1B | $1.9B |
| Dividends paid | $2.5B | $2.7B | $3.0B | $3.2B | $3.4B | $3.6B | $3.7B | $3.8B | $3.9B | $4.0B |
| Diluted shares | 1.4B | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B |
Source: SEC filings (10-K XBRL). EPS and share counts are split-adjusted.
What's priced into GILD?
A reverse DCF asks what growth the current price requires. With an enterprise value of $214.8B and $12.9B of trailing free cash flow, Gilead Sciences needs to grow free cash flow about 5.9% a year for ten years (fading to 3.0% terminal growth) to earn a 10% annual return. For context, free cash flow grew 4.7% a year over the last five years.
P/E ratio history
Current 23.0x vs. median 18.7x (10th–90th percentile 8.3x–286.0x).
A model, not a forecast or advice. Small changes in assumptions move the answer a lot.
GILD dividend
- Dividend yield
- 2.10%
- Annual dividend
- $3.28
- Years of increases
- 10
- 5-yr dividend growth
- 3.0%
- per year
- Payout ratio
- 43%
- Payments per year
- 4
Regular dividends per share by calendar year; special dividends excluded. Current year omitted until complete.
GILD analyst price targets
26 analysts' average 12-month target is $160.19 (+3% vs. $156.04). Targets range from $126.00 to $185.00. 79% rate it a buy.
GILD earnings
Next report: October 29, 2026. Gilead Sciences has beaten EPS estimates 8 quarters in a row. Last quarter's revenue was $7.8B (+10% year over year).
| Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|
| Aug 4, 2026 | $-7.25 | $-6.75 | +6.9% |
| May 7, 2026 | $1.91 | $2.03 | +6.2% |
| Feb 10, 2026 | $1.81 | $1.86 | +2.8% |
| Oct 30, 2025 | $2.14 | $2.47 | +15.7% |
| Aug 7, 2025 | $1.96 | $2.01 | +2.7% |
| Apr 24, 2025 | $1.78 | $1.81 | +1.9% |
| Feb 11, 2025 | $1.70 | $1.90 | +11.7% |
| Nov 6, 2024 | $1.55 | $2.02 | +30.5% |
Stocks like GILD
| Name | Today | 1Y | Mkt cap | P/E | |
|---|---|---|---|---|---|
 ABBV AbbVie | +0.16% | +29% | $504.8B | 80.7x | Compare |
 AMGN Amgen | -1.79% | +54% | $237.5B | 27.3x | Compare |
 VRTX Vertex Pharmaceuticals Incorpor | -2.10% | +24% | $132.8B | 29.9x | Compare |
 REGN Regeneron Pharmaceuticals | -1.72% | +41% | $82.9B | 19.9x | Compare |
 MRNA Moderna | -1.25% | +662% | $79.9B | — | Compare |
 BIIB Biogen | -1.24% | +67% | $37.0B | 44.5x | Compare |
 INCY Incyte | -1.04% | +30% | $23.5B | 14.7x | Compare |
 LLY Eli Lilly and | -2.54% | +56% | $1.1T | 42.7x | Compare |
GILD news
- BioNTech (BNTX) Reworks Phase 3 Breast Cancer Trial Around New Combination Approach · Oct 25, 2026
- Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy? · Oct 25, 2026
- Gilead Sciences (GILD) Could Be 22% Overvalued Following Its Liver Meeting Update · Oct 24, 2026
- Stocktwits Biotech Dealmaker: Gilead And Roche Double Down On Early-Stage Assets Over Full Buyouts This Week · Oct 24, 2026
- The Lanier Law Firm Supports Attorney General Ken Paxton in Reaching $45 Million Settlement with Gilead in Unlawful Inducement Scheme · Oct 23, 2026
GILD stock FAQ
What is GILD's market cap?
Gilead Sciences's market capitalization is $193.48 billion as of October 23, 2026, ranking 58th in the S&P 500.
Does GILD pay a dividend?
Yes. Gilead Sciences pays $3.28 per share a year, a 2.10% yield. It has raised its dividend 10 years in a row. Dividends grew 3.0% a year over the last five years.
How much has GILD stock returned?
Including reinvested dividends, GILD returned +32.4% over one year, +22.6% a year over five years, +11.6% a year over ten years through October 23, 2026.
Is GILD stock overvalued?
At today's price, a reverse discounted cash flow model (10% discount rate, 3% terminal growth) implies Gilead Sciences must grow free cash flow about 6% a year for the next decade. Its free cash flow grew 5% a year over the last five years. Whether that is achievable decides if the stock is cheap or expensive. This is a model, not advice.
What is the GILD price target?
26 analysts cover GILD with an average 12-month price target of $160.19, +3% from the current price. 79% of them rate it a buy.
When does GILD report earnings?
Gilead Sciences is expected to report earnings on October 29, 2026. It has beaten EPS estimates 8 quarters in a row.
How many employees does Gilead Sciences have?
Gilead Sciences has about 17,000 full-time employees, or $1.8 million of revenue per employee.
Sources: SEC EDGAR filings, Yahoo Finance market data (delayed), FI Handbook calculations. Last close October 23, 2026. Methodology